122 related articles for article (PubMed ID: 38303207)
1. [A Case of Suspected Pure Red Cell Aplasia Due to Nivolumab Treatment for Unresectable Esophageal Cancer].
Ogawa R; Suzuki K; Saito K; Shinohara H; Atsuta Y; Miura A
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1786-1788. PubMed ID: 38303207
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab Rechallenge After Immune-related Adverse Events in Patients With Unresectable Advanced or Recurrent Esophageal Cancer.
Ueno K; Suzuki K; Saito K; Shinohara H; Miura A
In Vivo; 2024; 38(2):794-799. PubMed ID: 38418136
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitor-Induced Pure Red Cell Aplasia: A Review of 2 Cases in Metastatic Melanoma.
Rueda Prada L; Gavrancic T; Cadena Sanabria MO; Dumic I; Bourgeois K; King RL; Yan Y
Am J Case Rep; 2023 Nov; 24():e941789. PubMed ID: 37957950
[TBL] [Abstract][Full Text] [Related]
4. A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
Yuki A; Takenouchi T; Takatsuka S; Ishiguro T
Melanoma Res; 2017 Dec; 27(6):635-637. PubMed ID: 28872489
[TBL] [Abstract][Full Text] [Related]
5. Re-Challenging with Nivolumab in Metastatic Renal Cell Carcinoma After Immune-Related Interstitial Pneumonia: A Case Report.
Shibata Y; Noguchi G; Suzuki T; Osaka K; Umemoto S; Kishida T
Am J Case Rep; 2021 Aug; 22():e932924. PubMed ID: 34358221
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.
Guo Q; Gao J; Guo H; Xie J; Cheng J
Int Immunopharmacol; 2023 Jan; 114():109490. PubMed ID: 36459923
[TBL] [Abstract][Full Text] [Related]
7. Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review.
Nakamura H; Shionoya A; Arihara Y; Hayasaka N; Kubo T; Usami M; Sugita S; Uhara H; Takada K
Front Immunol; 2023; 14():1259071. PubMed ID: 37753079
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
[TBL] [Abstract][Full Text] [Related]
10. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.
Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y
Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355
[TBL] [Abstract][Full Text] [Related]
11. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
[TBL] [Abstract][Full Text] [Related]
12. Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin.
Gérard A; Romani S; Van-Obberghen E; Fresse A; Muzzone M; Parassol N; Boscagli A; Rocher F; Borchiellini D; Drici MD
Front Oncol; 2020; 10():1760. PubMed ID: 32984061
[TBL] [Abstract][Full Text] [Related]
13. Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance.
Yamamoto N; Nakanishi Y; Gemma A; Nakagawa K; Sakamoto T; Akamatsu A; Ohe Y
Cancer Sci; 2021 Nov; 112(11):4692-4701. PubMed ID: 34431585
[TBL] [Abstract][Full Text] [Related]
14. Role of eosinophilia in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab: Prediction of immune-related adverse events and favorable outcome.
Ueki Y; Ohshima S; Omata J; Yokoyama Y; Takahashi T; Shodo R; Yamazaki K; Horii A
Cancer Med; 2023 Nov; 12(22):20810-20820. PubMed ID: 37902133
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y; Ajani JA; Kato K; Xu J; Wyrwicz L; Motoyama S; Ogata T; Kawakami H; Hsu CH; Adenis A; El Hajbi F; Di Bartolomeo M; Braghiroli MI; Holtved E; Ostoich SA; Kim HR; Ueno M; Mansoor W; Yang WC; Liu T; Bridgewater J; Makino T; Xynos I; Liu X; Lei M; Kondo K; Patel A; Gricar J; Chau I; Kitagawa Y;
N Engl J Med; 2022 Feb; 386(5):449-462. PubMed ID: 35108470
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
[TBL] [Abstract][Full Text] [Related]
17. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer.
Kato T; Masuda N; Nakanishi Y; Takahashi M; Hida T; Sakai H; Atagi S; Fujita S; Tanaka H; Takeda K; Satouchi M; Namba Y; Tamura T
Lung Cancer; 2017 Feb; 104():111-118. PubMed ID: 28212992
[TBL] [Abstract][Full Text] [Related]
19. Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors: A Case Report.
Hirai T; Inomata M; Minatoyama S; Hashizume M; Takata N; Hayashi K; Seto Z; Tokui K; Taka C; Okazawa S; Kambara K; Imanishi S; Miwa T; Hayashi R; Tanaka S; Noguchi A; Sato T
In Vivo; 2024; 38(3):1509-1511. PubMed ID: 38688637
[TBL] [Abstract][Full Text] [Related]
20. Niraparib-induced pure red cell aplasia.
Bir Yücel K; Yıldız S; Sütcüoglu O; Güvercin FS; Uyar Göçün P; Özdemir N; Yazıcı O; Özet A
J Oncol Pharm Pract; 2024 Jan; 30(1):210-214. PubMed ID: 37642988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
